{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-036519","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.302266+00:00","generated_at":"2026-05-15T08:28:47.142426+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TherapeuticsMD reports 2025 full-year net loss of $0.7M, license revenue up 71.6% to $3.0M","bullets":["Net loss from continuing operations narrowed to $0.7M ($0.06 per share) from $2.3M in 2024.","License revenue rose 71.6% to $3.0M, primarily driven by the Mayne License Agreement.","Total operating expenses decreased 5.9% to $7.4M, partly due to lower impairment charges.","Cash and cash equivalents stood at $7.5M as of December 31, 2025.","Company continues to evaluate strategic alternatives including M&A or sale of assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-036519","json":"https://secwatch.observer/filing/0001213900-26-036519.json","markdown":"https://secwatch.observer/filing/0001213900-26-036519.md","text":"https://secwatch.observer/filing/0001213900-26-036519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/0001213900-26-036519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/ea0283239-8k_therapeu.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:28:47.142426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc57e8c0c24b6aa1dafd5579c36beb333a6f6117","claim":"TherapeuticsMD, Inc. reported the full year ended December 31, 2025 results: revenue $3.0 million, net income $(0.7) million, EPS $(0.06) per basic and diluted common share.","evidence_excerpt":"or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations ● License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/0001213900-26-036519-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Revenue","value":"$3.0 million"},{"label":"Net income","value":"$(0.7) million"},{"label":"EPS","value":"$(0.06) per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}